Research Topics
| E L EisensteinSummaryAffiliation: Duke University Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Sensible approaches for reducing clinical trial costsEric L Eisenstein
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Clin Trials 5:75-84. 2008..Over the past decade, annual funding for biomedical research has more than doubled while new molecular entity approvals have declined by one third...
Obesity and long-term clinical and economic outcomes in coronary artery disease patientsEric L Eisenstein
The Outcomes Research and Assessment Group, The Duke Clinical Research Institute, Durham, North Carolina 27715, USA
Obes Res 10:83-91. 2002..We assessed the impact of increasing body mass index (BMI) on 10-year outcomes for ACS patients...
Conducting an economic analysis to assess the electrocardiogram's valueEric L Eisenstein
Outcomes Research and Assessment Group, Duke Clinical Research Institute, Durham, NC 27715, USA
J Electrocardiol 39:241-7. 2006..Health economic analyses seek to assess the relative value (cost vs health benefit trade-offs) of medical technologies. However, these methods have been underused in studies of the electrocardiogram (ECG)...
Elevated body mass index and intermediate-term clinical outcomes after acute coronary syndromesEric L Eisenstein
Duke University Medical Center and the Duke Clinical Research Institute, Durham, NC 27715, USA
Am J Med 118:981-90. 2005..We evaluated the relationship between elevated body mass index (BMI) and 30-day, 90-day, and 1-year clinical outcomes postacute coronary syndromes...
Do income level and race influence survival in patients receiving hemodialysis?Eric L Eisenstein
Duke Clinical Research Institute, Durham, NC 27715, USA
Am J Med 122:170-80. 2009..We sought to determine whether these differences persist and whether the effect of income-area on mortality is different for African Americans versus patients of other races...
Surgeons' economic profiles: can we get the "right" answers?Eric L Eisenstein
Outcomes Research and Assessment Group, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, 27715 7969, USA
J Med Syst 29:111-24. 2005..Adjusting for patient-mix differences and treating surgeons as random effects was the preferred approach. These results demonstrate the need for hospitals to reexamine their economic profiling methods...
Reducing the costs of phase III cardiovascular clinical trialsEric L Eisenstein
Division of Cardiology, Department of Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27715, USA
Am Heart J 149:482-8. 2005..1 billion dollars in cardiovascular products). We compared pharmaceutical companies' planned resource use and costs in Phase III cardiovascular trials and identified cost-saving strategies...
Evaluating the potential 'economic attractiveness' of new therapies in patients with non-ST elevation acute coronary syndromeE L Eisenstein
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
Pharmacoeconomics 17:263-72. 2000..To evaluate the relationship between how much a new cardiovascular therapy improves clinical outcomes over current therapies and how much more it can cost while still remaining 'economically attractive'...
Assessing the clinical and economic burden of coronary artery disease: 1986-1998E L Eisenstein
Outcomes Research and Assessment Group, The Duke Clincal Research Institute, Durham, NC, USA
Med Care 39:824-35. 2001..We compared the clinical and economic burden of CAD during the acute phase (first 30 days) with that in the postacute phase (31st day through 10 years)...
Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarctionPadma Kaul
Department of Medicine, Duke Clinical Research Institute, Durham, NC, USA
Am Heart J 149:637-44. 2005....
Cost effectiveness of early discharge after uncomplicated acute myocardial infarctionL K Newby
Duke Clinical Research Institute, Durham, NC 27715 7969, USA
N Engl J Med 342:749-55. 2000..Reducing the length of hospitalizations can reduce short-term costs, but there are few data on the long-term clinical and economic consequences of early discharge...
The use of patient mix-adjusted control charts to compare in-hospital costs of careE L Eisenstein
Duke University Medical Center, Durham, NC 27710, USA
Health Care Manag Sci 2:193-8. 1999..After adjustment, two months had average costs outside the 90% lower control limit lines, and the trend toward increasing costs had been explained by differences in patient acuity...
Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research DatabaseJohn L Petersen
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA
Am Heart J 159:462-470.e1. 2010..Relationships between long-term use and level of dual antiplatelet therapy and outcomes after drug-eluting stent implantation are not well established...
What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trialEric L Eisenstein
The Outcomes Research and Assessment Group, The Duke Clinical Research Institute, Durham, North Carolina 27715, USA
J Card Fail 12:336-42. 2006..At 37 months average follow-up, patients in both groups had similar mortality. We determined the incremental costs associated with the use of digoxin in this high-risk population...
Advanced coronary artery disease: Appropriate end points for trials of novel therapiesD E Kandzari
Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Am Heart J 142:843-51. 2001..Because the natural history of these patients is less defined, the appropriate end points for trials of novel revascularization therapies involving patients with advanced coronary artery disease are not certain...
Long-term clinical outcomes following coronary stentingKevin J Anstrom
Department of Biostatistics, Duke Clinical Research Institute, Durham, NC 27715, USA
Arch Intern Med 168:1647-55. 2008..The objective of this study was to compare the long-term clinical outcomes of patients receiving DES vs BMS in a clinical practice setting...
Late adverse events after drug-eluting stent implantationDavid F Kong
Duke Clinical Research Institute, DUMC Box 3850, Durham, NC 27710, USA
Curr Cardiol Rep 10:253-62. 2008..This timely, robust evidence base reflects an alignment of academic, industry, and public health priorities...
Re-evaluating the volume-outcome relationship in hemodialysis patientsEric L Eisenstein
Duke Clinical Research Institute, 2400 Pratt Street, Room 0311, Durham, NC 27705, USA
Health Policy 88:317-25. 2008..We sought to determine whether dialysis patient mortality rates are associated with differences in dialysis facility size, and whether this relationship differs among higher risk diabetic and lower-risk non-diabetic patients...
Economic assessment of thrombocytopenia: CATCH RegistryEric L Eisenstein
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
J Med Syst 34:379-86. 2010..001); and (group 3) (difference, $27,077; 95% CI, $22,901-$31,252; P<.001). However, in our adjusted model, longer lengths-of-stay and greater use of blood transfusions accounted for most incremental in-hospital cost differences...
DRIVE it home: making the case for prospective economic data collection in randomized clinical trialsEric L Eisenstein
Duke Clinical Research Institute, Durham, North Carolina 27715, USA
Kidney Int 74:1507-9. 2008....
Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting CoronaryEric L Eisenstein
Duke Clinical Research Institute, Durham, North Carolina 27705, USA
JACC Cardiovasc Interv 2:1199-207. 2009....
Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data RegistryPamela S Douglas
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
J Am Coll Cardiol 53:1629-41. 2009..The aim of this study was to compare outcomes in older individuals receiving drug-eluting stents (DES) and bare-metal stents (BMS)...
Assessing the economic attractiveness of coronary artery revascularization in chronic kidney disease patientsEric L Eisenstein
Duke University Medical Center, Durham, NC 27715, USA
J Med Syst 33:287-97. 2009..Medical therapy was an economically attractive strategy vs. CABG surgery or PCI for three-vessel CAD patients with CKD, two-vessel CAD patients without CKD, and all single-vessel CAD patients...
Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 ElutingEric L Eisenstein
Duke Clinical Research Institute, Durham, North Carolina 27705, USA
JACC Cardiovasc Interv 2:1178-87. 2009..This study was designed to evaluate long-term clinical and economic outcomes for subjects receiving Endeavor drug-eluting versus Driver bare-metal stents (both Medtronic CardioVascular, Santa Rosa, California)...
Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromesSunil V Rao
The Duke Clinical Research Institute, Durham, NC 27705, USA
Am Heart J 155:369-74. 2008..We sought to determine the relationship between bleeding, blood transfusion, and measures of costs among patients with non-ST-segment elevation ACS...
Decision models for assessing the cost effectiveness of drug-eluting stentsDavid F Kong
Duke University Medical Centre, Duke Clinical Research Institute, DUMC Box 3850, Durham, NC 27710, USA
Expert Opin Pharmacother 6:965-74. 2005..More research is recommended to identify high-risk patients who stand to gain significant health benefits from this therapy...
A problem-based approach to teaching outcomes research in family medicine residencyTruls Ostbye
Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27110, USA
Fam Med 36:470-2. 2004..This study's objective was to introduce research concepts and skills in family medicine residency through a problem-based course...
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantationEric L Eisenstein
Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
JAMA 297:159-68. 2007..Recent studies of drug-eluting intracoronary stents suggest that current antiplatelet regimens may not be sufficient to prevent late stent thrombosis...
Economic return of clinical trials performed under the pediatric exclusivity programJennifer S Li
Department of Pediatrics, Duke Clinical Research Institute, Duke University, Durham, NC 27705, USA
JAMA 297:480-8. 2007..This critique has been a substantial part of congressional debate on the program, which is due to expire in 2007...
Economic impact of drug-eluting stents on hospital systems: a disease-state modelDavid F Kong
Duke Clinical Research Institute, DUMC, Durham, NC 27710, USA
Am Heart J 147:449-56. 2004..The US Department of Health and Human Services (HHS), recognizing the financial and clinical impact of this technology, recently proposed accelerated reimbursement to hospitals...
Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databasesLesley H Curtis
Duke Clinical Research Institute, and Departments of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
Med Care 45:S103-7. 2007..Finally, we offer detailed guidance about how to implement the estimators in comparative effectiveness analyses...
Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart FailureEric L Eisenstein
Outcomes Research and Assessment Group, Duke Clinical Research Institute, Durham, NC 27705, USA
Am Heart J 143:1112-7. 2002..They also had significantly fewer serious cardiac adverse events...
Outcomes of second revascularization procedures after stent implantationRichard P Konstance
Department of Medicine, Duke University Medical Center, Durham, NC, USA
J Med Syst 32:177-86. 2008..Further studies are needed to determine the optimum application for CABG vs. DES as a second or third revascularization procedure...
Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-IISana M Al-Khatib
Duke Clinical Research Institute, Durham, North Carolina 27715, USA
Ann Intern Med 142:593-600. 2005..However, in the range of survival benefit observed in MADIT-II, ICD therapy for these patients is economically attractive by conventional standards...
Relationship between anemia and health care costs in heart failureLarry A Allen
Division of Cardiology, University of Colorado Denver, Aurora, Colorado 80045, USA
J Card Fail 15:843-9. 2009..Anemia is associated with higher morbidity and mortality in patients with heart failure (HF), but its implications for heath care costs are not well described...
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapyGustavo B F Oliveira
Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt St, Durham, NC 27705, USA
Arch Intern Med 168:94-102. 2008..Despite widespread heparin use in clinical practice, the associated development of thrombocytopenia is an underrecognized and undertreated complication...
Local cost structures and the economics of robot assisted radical prostatectomyCharles D Scales
Division of Urology, Department of Surgery, Duke Prostate Center, Duke University Medical Center, Durham, NC 27710, USA
J Urol 174:2323-9. 2005..While RAP may be cost competitive with RRP at high cost hospitals or high volume RAP specialist centers, this procedure would exist at a cost premium to RRP in other practice settings...
The economic returns of pediatric clinical trials of antihypertensive drugsCarissa M Baker-Smith
Department of Pediatrics, Duke University Medical Center, Durham, NC, USA
Am Heart J 156:682-8. 2008..We sought to determine the cost of performing pediatric exclusivity trials within a single therapeutic area and the subsequent economic return to industry sponsors...
A randomized clinical trial of clinical decision support in a rural community health network serving lower income individuals: study design and baseline characteristicsEric L Eisenstein
Duke Clinical Research Institute, Durham, NC, USA
Stud Health Technol Inform 143:220-6. 2009..We propose to achieve these improvements by implementing system-to-system integration via a telehealth network with an asynchronous clinical decision support system for health care providers...
Problem-based learning of research skillsThomas H Davis
Duke University Medical Center, Durham, NC 27705, USA
J Electrocardiol 39:120-8. 2006..Further, more rigorous structured research is needed to determine the ultimate impact on practice change and patient outcomes...
Effect of medical management on recurrent stone formation following percutaneous nephrolithotomyDavid E Kang
Comprehensive Kidney Stone Center, Duke University Medical Center, Durham, North Carolina 27710, USA
J Urol 177:1785-8; discussion 1788-9. 2007..Thus, we have conducted the first investigation of aggressive medical management following percutaneous nephrolithotomy and its impact on stone formation rates in patients with and without residual fragments...
Percutaneous transluminal septal reduction for hypertrophic obstructive cardiomyopathy: report from an international pilot studyHope E Buell
The Outcomes Research and Assessment Group, Duke Clinical Research Institute, Durham, North Carolina, USA
J Med Syst 26:293-300. 2002....
Research Grants
- Dialysis Facility ManagementEric Eisenstein; Fiscal Year: 2003..abstract_text> ..
